Longer Term Results from a Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia (ENCORE-VT)
A prospective phase I/II trial of noninvasive cardiac radioablation in high risk patients with treatment-refractory episodes of ventricular arrhythmias demonstrated acceptable primary endpoint 90-day and 6-month safety profile with 11% serious adverse event (SAE) rate, 94% reduction in ventricular tachycardia (VT) episodes, and 89% 6-month overall survival (OS). Longer-term safety and efficacy of this technique is reported.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: C.G. Robinson, P. Samson, K.M.S. Moore, G.D. Hugo, N. Knutson, S. Mutic, S.M. Goddu, D.H. Cooper, M. Faddis, A. Noheria, T.W. Smith, P.K. Woodard, R.J. Gropler, D.E. Hallahan, Y. Rudy, P. Cuculich Source Type: research
More News: Arrhythmia | Biology | Cancer & Oncology | Physics | Radiology | Study | Ventricular Tachycardia